These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 22313815

  • 1. Zoledronic acid and osteonecrosis of the jaw: incidence varies with use.
    Wynn RL.
    Gen Dent; 2011; 59(5):330-2. PubMed ID: 22313815
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Fitzpatrick SG, Stavropoulos MF, Bowers LM, Neuman AN, Hinkson DW, Green JG, Bhattacharyya I, Cohen DM.
    J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Paget's disease and bisphosphonate-associated osteonecrosis of the jaws.
    Gueiros LA, Lopes MA, Leão JC.
    J Oral Maxillofac Surg; 2008 Jun; 66(6):1319. PubMed ID: 18486809
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Medication-related osteonecrosis of the jaws from once per year intravenous zoledronic acid (Reclast): report of 4 cases.
    Lee CY, Suzuki JB.
    Implant Dent; 2015 Apr; 24(2):227-31. PubMed ID: 25734948
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: a case report solved with non-invasive treatment.
    Gómez-Moreno G, Arribas-Fernández MC, Fernández-Guerrero M, Boquete-Castro A, Aguilar-Salvatierra A, Guardia J, Botticelli D, Calvo-Guirado JL.
    Eur Rev Med Pharmacol Sci; 2014 Apr; 18(9):1391-7. PubMed ID: 24867519
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Osteonecrosis of the jaw.
    Reilly MM, Moore S.
    Oncology (Williston Park); 2008 Feb; 22(2 Suppl Nurse Ed):39-41. PubMed ID: 18431898
    [No Abstract] [Full Text] [Related]

  • 17. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) associated with a once-yearly IV infusion of zoledronic acid (Reclast) 5 mg: two cases and review of the literature.
    Katz J, Ordoveza PA.
    Quintessence Int; 2014 Sep; 45(8):685-90. PubMed ID: 25019116
    [Abstract] [Full Text] [Related]

  • 18. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
    Higuchi T, Soga Y, Muro M, Kajizono M, Kitamura Y, Sendo T, Sasaki A.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun; 125(6):547-551. PubMed ID: 29574058
    [Abstract] [Full Text] [Related]

  • 19. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
    Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C.
    Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.